Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

C Daruwalla; V Shaygannejad; S Ozakbas; EK Havrdova; D Horakova; R Alroughani; C Boz; F Patti; M Onofrj; A Lugaresi; S Eichau; M Girard; A Prat; P Duquette; B Yamout; SJ Khoury; SA Sajedi; R Turkoglu; A Altintas; O Skibina; K Buzzard; P Grammond; R Karabudak; A van der Walt; H Butzkueven; D Maimone; J Lechner-Scott; A Soysal; N John; J Prevost; D Spitaleri; C Ramo-Tello; O Gerlach; G Iuliano; M Foschi; R Ampapa; V van Pesch; M Barnett; N Shalaby; M D’hooghe; J Kuhle; MJ Sa; M Fabis-Pedrini; A Kermode; S Mrabet; R Gouider; S Hodgkinson; G Laureys; L Van Hijfte; R Macdonell; C Oreja-Guevara; E Cristiano; P McCombe; JL Sanchez-Menoyo; B Singhal; Y Blanco; S Hughes; J Garber; C Solaro; C McGuigan; B Taylor; K de Gans; M Habek; A Al-Asmi; S Mihaela; T Castillo Triviño; T Al-Harbi; JI Rojas; O Gray; D Khurana; B Van Wijmeersch; N Grigoriadis; J Inshasi; J Oh; E Aguera-Morales; Y Fragoso; F Moore; C Shaw; SM Baghbanian; N Shuey; B Willekens; TA Hardy; D Decoo; AP sempere; D Field; R Wynford-Thomas; NG Cunniffe; I Roos; CB Malpas; AJ Coles; T Kalincik; JWL Brown

Journal article

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, R Alroughani, C Boz, F Patti, M Onofrj, A Lugaresi, S Eichau, M Girard, A Prat, P Duquette, B Yamout, SJ Khoury, SA Sajedi, R Turkoglu, A Altintas, O Skibina Show all

Multiple Sclerosis Journal | Published : 2023

DOI: 10.1177/13524585231151951

Abstract

Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS. Methods: We redefined mild relapses in MSBase as ‘non-disabling’, and moderate or severe relapses as ‘disabling’. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. Results: People ..

View full abstract

University of Melbourne Researchers

Richard MacDonell Author

Neil Shuey Author

Izanne Roos Author

Charles Malpas Author

Related Projects (3)

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Grants

Awarded by Merck

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by National Health and Medical Research Council of Australia (fellowship nos.1140766 and 1080518, project grant nos. 1129189 and 1083539), the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship), National Institute for Health and Care Research (UK) Advanced Fellowship (grant no. 301728; recipient JWLB) and Academic Clinical Fellowship (grant no. EAN/ACA-006/7488627/C; recipient CD). The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme, and Teva. Role of the Funder/Sponsor: The National Health and Medical Research Council of Australia, the University of Melbourne and the National Institute for Health and Care Research (UK) had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manu-script for publication.